{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:57Z","timestamp":1791328917093,"version":"4.3.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.mce.2011.06.025","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T15:38:13Z","timestamp":1311262693000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics"],"prefix":"10.1016","volume":"350","author":[{"given":"Peter","family":"Kolkhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen A.","family":"Borden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2011.06.025_b0015","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2011.06.025_b0020","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines","volume":"53","author":"Arhancet","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0025","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0303-7207(97)00115-9","article-title":"Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin","volume":"131","author":"Bamberger","year":"1997","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0035","doi-asserted-by":"crossref","first-page":"37747","DOI":"10.1074\/jbc.M507464200","article-title":"Structural basis for accommodation of nonsteroidal ligands in the androgen receptor","volume":"280","author":"Bohl","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/FJC.0b013e3181953e65","article-title":"Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure","volume":"53","author":"Brandish","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0045","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/jps.2600650919","article-title":"Binding of spirolactones to human plasma proteins","volume":"65","author":"Chien","year":"1976","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.mce.2011.06.025_b0050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.mce.2011.06.025_b0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"issue":"Pt 3","key":"10.1016\/j.mce.2011.06.025_b0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj2820697","article-title":"Aldosterone antagonists destabilize the mineralocorticosteroid receptor","volume":"282","author":"Couette","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.mce.2011.06.025_b0065","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mce.2011.06.025_b0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.mce.2011.06.025_b0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0008-6363(99)00088-7","article-title":"Aldosterone and the heart: towards a physiological function?","volume":"43","author":"Delcayre","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.mce.2011.06.025_b0080","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","article-title":"Effect of a selective aldosterone receptor antagonist in myocardial infarction","volume":"281","author":"Delyani","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.mce.2011.06.025_b0085","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2011.06.025_b0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/jcem-53-1-58","article-title":"Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma","volume":"53","author":"Dunn","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2011.06.025_b0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","article-title":"Conception and pharmacodynamic profile of drospirenone","volume":"68","author":"Elger","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.mce.2011.06.025_b0100","unstructured":"Ergueden, J.K., Kolkhof, P., Sandner, P., Kuhl, A., Stasch, J.P., Pook, E., Schlemmer, K.H., 2005. Fluorenone 1, 4,-Dihydropyridin Derivatives, WO\/2005\/087740, Bayer Healthcare AG, Germany."},{"key":"10.1016\/j.mce.2011.06.025_b0105","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0110","doi-asserted-by":"crossref","first-page":"F1462","DOI":"10.1152\/ajprenal.00285.2010","article-title":"Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP","volume":"299","author":"Faresse","year":"2010","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.mce.2011.06.025_b0115","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/en.2006-1438","article-title":"Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling?","volume":"148","author":"Fejes-Toth","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2011.06.025_b0120","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.mce.2011.06.025_b0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/13543784.15.3.201","article-title":"The aldosterone receptor\u2013new insights?","volume":"15","author":"Fuller","year":"2006","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.mce.2011.06.025_b0130","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","article-title":"Mechanisms of mineralocorticoid action","volume":"46","author":"Fuller","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2011.06.025_b0135","first-page":"39","article-title":"Steroids, hypertension and cardiac fibrosis","volume":"2","author":"Funder","year":"1995","journal-title":"Blood Press Suppl."},{"key":"10.1016\/j.mce.2011.06.025_b0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ncpendmet0016","article-title":"Mineralocorticoid-receptor blockade, hypertension and heart failure","volume":"1","author":"Funder","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2011.06.025_b0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2011.06.025_b0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.ph.49.030187.002145","article-title":"Adrenocortical steroids and the brain","volume":"49","author":"Funder","year":"1987","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.mce.2011.06.025_b0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.mce.2011.06.025_b0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11906-001-0049-z","article-title":"Role of central mineralocorticoid receptors in cardiovascular disease","volume":"3","author":"Gomez-Sanchez","year":"2001","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.mce.2011.06.025_b0170","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2005.06.032","article-title":"Role of endocytosis in cellular uptake of sex steroids","volume":"122","author":"Hammes","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.mce.2011.06.025_b0175","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2011.06.025_b0180","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/en.2010-0099","article-title":"The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals","volume":"151","author":"Hernandez-Diaz","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2011.06.025_b0185","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1389557054553811","article-title":"Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone","volume":"5","author":"Hu","year":"2005","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0190","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0195","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.107.036459","article-title":"Structural basis of spirolactone recognition by the mineralocorticoid receptor","volume":"72","author":"Huyet","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0010","unstructured":"Inspra Drug Approval Package, 2003. Pharmacological Review Inspra Drug Approval Package 21-437\/S-002, FDA US Food and Drug Administration, <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-437S002_Inspra_Pharmr.pdf>."},{"key":"10.1016\/j.mce.2011.06.025_b0005","unstructured":"Inspra prescribing information, 2002. INSPRA (eplerenone) tablets: Prescribing information, FDA US Food and Drug Administration, <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021437s006lbl.pdf>."},{"key":"10.1016\/j.mce.2011.06.025_b0200","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2011.06.025_b0205","doi-asserted-by":"crossref","first-page":"35123","DOI":"10.1074\/jbc.M110.121301","article-title":"Human sodium phosphate transporter 4 (hNPT4\/SLC17A3) as a common renal secretory pathway for drugs and urate","volume":"285","author":"Jutabha","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1210\/endo-67-1-125","article-title":"Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone","volume":"67","author":"Kagawa","year":"1960","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2011.06.025_b0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metab. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.mce.2011.06.025_b0220","first-page":"544","article-title":"New aspect of calcium channel blockers: How azelnidipine inhibits mineralocorticoid receptor activity","volume":"57","author":"Kawarazaki","year":"2010","journal-title":"Endocr. J."},{"key":"10.1016\/j.mce.2011.06.025_b0225","series-title":"Nuclear Receptors as Drug Targets","first-page":"409","article-title":"Nuclear receptors as targets in cardiovascular diseases","author":"Kolkhof","year":"2008"},{"key":"10.1016\/j.mce.2011.06.025_b0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","article-title":"The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family","volume":"635","author":"Kosaka","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00543796","article-title":"Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses","volume":"25","author":"Krause","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.mce.2011.06.025_b0240","first-page":"328","article-title":"Dihydropyridine calcium channel blockers have selective antagonist activity of steroid hormone receptors through blocking nuclear translocation of the receptor","volume":"57","author":"Kurihara","year":"2010","journal-title":"Endocr. J."},{"key":"10.1016\/j.mce.2011.06.025_b0245","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/jcem-18-11-1237","article-title":"Inhibition of the sodium-retaining influence of aldosterone by progesterone","volume":"18","author":"Landau","year":"1958","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2011.06.025_b0250","first-page":"1583","article-title":"Mespirenone and other 15, 16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists","volume":"36","author":"Losert","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.mce.2011.06.025_b0255","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200724060-00002","article-title":"Drospirenone, a new progestogen, for postmenopausal women with hypertension","volume":"24","author":"Mallareddy","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.mce.2011.06.025_b0260","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1963.73700230005018","article-title":"Gynecomastia during therapy with spironolactone","volume":"184","author":"Mann","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2011.06.025_b0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2010.04.149","article-title":"Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity","volume":"396","author":"Matsui","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mce.2011.06.025_b0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0275","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","article-title":"Discovery of (3S, 3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3, 3a, 4, 5-tetrahydro-2H-b enzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy","volume":"53","author":"Meyers","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mce.2011.06.025_b0280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/13543776.17.1.17","article-title":"Non-steroidal mineralocorticoid receptor antagonists","volume":"17","author":"Meyers","year":"2007","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.mce.2011.06.025_b0285","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/13543784.14.12.1527","article-title":"New and improved glucocorticoid receptor ligands","volume":"14","author":"Miner","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mce.2011.06.025_b0290","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models","volume":"51","author":"Muhn","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.mce.2011.06.025_b0295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1124\/mol.65.3.761","article-title":"DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells\u2013toward a basis for the opposite actions elicited by two nuclear receptors?","volume":"65","author":"Obradovic","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0300","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women","volume":"73","author":"Oelkers","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2011.06.025_b0305","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/0006-2952(83)90347-7","article-title":"Uptake of [3H]nitrendipine into cardiac and smooth muscles","volume":"32","author":"Pang","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0310","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.mce.2011.06.025_b0315","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/me.2005-0089","article-title":"The mineralocorticoid receptor: a journey exploring its diversity and specificity of action","volume":"19","author":"Pascual-Le Tallec","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0320","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/me.2004-0331","article-title":"The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions","volume":"19","author":"Pascual-Le Tallec","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2008.03.009","article-title":"Clinical experiences with drospirenone: from reproductive to postmenopausal years","volume":"60","author":"Perez-Lopez","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.mce.2011.06.025_b0330","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1161\/01.CIR.0000086776.15268.22","article-title":"Aldosterone blockade in patients with systolic left ventricular dysfunction","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2011.06.025_b0335","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrcardio.2009.175","article-title":"Pharmacotherapy: cardiovascular effects of aldosterone blockade in CKD","volume":"6","author":"Pitt","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.mce.2011.06.025_b0340","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2011.06.025_b0345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure, randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2011.06.025_b0350","first-page":"1801","article-title":"Studies on organ- and subcellular distribution of 3 H-spironolactone in animals","volume":"22","author":"Platt","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.mce.2011.06.025_b0355","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0960-0760(92)90430-Q","article-title":"Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor","volume":"41","author":"Rafestin-Oblin","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mce.2011.06.025_b0360","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.mce.2011.06.025_b0365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0303-7207(98)00226-3","article-title":"Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2","volume":"148","author":"Russell","year":"1999","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2009.244","article-title":"Heart failure: aldosterone antagonists are underused by clinicians","volume":"7","author":"Samuel","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.mce.2011.06.025_b0375","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mce.2011.06.025_b0380","first-page":"E224","article-title":"Mineralocorticoid specificity of renal type I receptors: in vivo binding studies","volume":"252","author":"Sheppard","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.mce.2011.06.025_b0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.mce.2011.06.025_b0390","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mce.2011.06.025_b0395","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites","volume":"102","author":"Sungaila","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mce.2011.06.025_b0400","series-title":"Immediate Release Eplerenone Compositions, US 6, 558, 707(B1), G.D","author":"Thosar","year":"2003"},{"key":"10.1016\/j.mce.2011.06.025_b0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mce.2007.01.010","article-title":"Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor","volume":"268","author":"Tirard","year":"2007","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0410","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","article-title":"Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation","volume":"55","author":"Tsai","year":"2010","journal-title":"J. Am. Coll Cardiol."},{"key":"10.1016\/j.mce.2011.06.025_b0415","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF00544063","article-title":"Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism","volume":"28","author":"Ulmann","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2011.06.025_b0420","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1046\/j.1523-1755.2000.00962.x","article-title":"Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms","volume":"57","author":"Verrey","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.mce.2011.06.025_b0425","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.mce.2011.06.025_b0430","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1677\/JME-09-0031","article-title":"The mineralocorticoid receptor and its coregulators","volume":"43","author":"Yang","year":"2009","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.mce.2011.06.025_b0435","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1081\/ERC-200043783","article-title":"Proteasome-mediated mineralocorticoid receptor degradation attenuates transcriptional response to aldosterone","volume":"30","author":"Yokota","year":"2004","journal-title":"Endocr. Res."},{"key":"10.1016\/j.mce.2011.06.025_b0440","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1527-5299.2005.03722.x","article-title":"Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure","volume":"11","author":"Yoshida","year":"2005","journal-title":"Congest Heart Fail."},{"key":"10.1016\/j.mce.2011.06.025_b0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2011.06.025_b0450","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1096\/fj.09-134759","article-title":"Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel","volume":"23","author":"Ziera","year":"2009","journal-title":"FASEB J."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720711003583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720711003583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:01:40Z","timestamp":1759586500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720711003583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0303720711003583"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2011.06.025","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2011.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}